Cargando…
Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
β-Secretase1 (BACE1) catalyzes the rate-limiting step in the generation of amyloid-β peptides, that is, the principal component involved in the pathology of Alzheimer’s disease (AD). Recent research studies show correlation between blood and cerebrospinal fluid (CSF) levels of BACE1 with the pathoph...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987718/ https://www.ncbi.nlm.nih.gov/pubmed/35402415 http://dx.doi.org/10.3389/fbioe.2022.873811 |
_version_ | 1784682803833602048 |
---|---|
author | Dey, Jhilik Roberts, Akanksha Mahari, Subhasis Gandhi, Sonu Tripathi, Prem Prakash |
author_facet | Dey, Jhilik Roberts, Akanksha Mahari, Subhasis Gandhi, Sonu Tripathi, Prem Prakash |
author_sort | Dey, Jhilik |
collection | PubMed |
description | β-Secretase1 (BACE1) catalyzes the rate-limiting step in the generation of amyloid-β peptides, that is, the principal component involved in the pathology of Alzheimer’s disease (AD). Recent research studies show correlation between blood and cerebrospinal fluid (CSF) levels of BACE1 with the pathophysiology of AD. In this study, we report one-step synthesized reduced graphene oxide (rGO), activated via carbodiimide chemistry, conjugated with BACE1 antibody (Ab), and immobilized on fluorine-doped tin oxide (FTO) electrodes for rapid detection of BACE1 antigen (Ag) for AD diagnosis. The synthesis and fabrication steps were characterized using different types of spectroscopic, X-ray analytic, microscopic, and voltametric techniques. Various parameters including nanomaterial/Ab concentration, response time, pH, temperature, and rate of scan were standardized for maximum current output using the modified electrode. Final validation was performed via detection of BACE1 Ag ranging from 1 fM to 1 µM, with a detection limit of 0.64 fM in buffer samples and 1 fM in spiked serum samples, as well as negligible cross-reactivity with neurofilament Ag in buffer, spiked serum, and spiked artificial CSF. The proposed immunosensor gave a quick result in 30 s, and good repeatability and storage stability for a month, making it a promising candidate for sensitive, specific, and early diagnosis of AD. Thus, the fabricated electrochemical biosensor for BACE-1 detection improves detection performance compared to existing sensors as well as reduces detection time and cost, signifying its potential in early diagnosis of AD in clinical samples. |
format | Online Article Text |
id | pubmed-8987718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89877182022-04-08 Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide Dey, Jhilik Roberts, Akanksha Mahari, Subhasis Gandhi, Sonu Tripathi, Prem Prakash Front Bioeng Biotechnol Bioengineering and Biotechnology β-Secretase1 (BACE1) catalyzes the rate-limiting step in the generation of amyloid-β peptides, that is, the principal component involved in the pathology of Alzheimer’s disease (AD). Recent research studies show correlation between blood and cerebrospinal fluid (CSF) levels of BACE1 with the pathophysiology of AD. In this study, we report one-step synthesized reduced graphene oxide (rGO), activated via carbodiimide chemistry, conjugated with BACE1 antibody (Ab), and immobilized on fluorine-doped tin oxide (FTO) electrodes for rapid detection of BACE1 antigen (Ag) for AD diagnosis. The synthesis and fabrication steps were characterized using different types of spectroscopic, X-ray analytic, microscopic, and voltametric techniques. Various parameters including nanomaterial/Ab concentration, response time, pH, temperature, and rate of scan were standardized for maximum current output using the modified electrode. Final validation was performed via detection of BACE1 Ag ranging from 1 fM to 1 µM, with a detection limit of 0.64 fM in buffer samples and 1 fM in spiked serum samples, as well as negligible cross-reactivity with neurofilament Ag in buffer, spiked serum, and spiked artificial CSF. The proposed immunosensor gave a quick result in 30 s, and good repeatability and storage stability for a month, making it a promising candidate for sensitive, specific, and early diagnosis of AD. Thus, the fabricated electrochemical biosensor for BACE-1 detection improves detection performance compared to existing sensors as well as reduces detection time and cost, signifying its potential in early diagnosis of AD in clinical samples. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8987718/ /pubmed/35402415 http://dx.doi.org/10.3389/fbioe.2022.873811 Text en Copyright © 2022 Dey, Roberts, Mahari, Gandhi and Tripathi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Dey, Jhilik Roberts, Akanksha Mahari, Subhasis Gandhi, Sonu Tripathi, Prem Prakash Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide |
title | Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide |
title_full | Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide |
title_fullStr | Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide |
title_full_unstemmed | Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide |
title_short | Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide |
title_sort | electrochemical detection of alzheimer’s disease biomarker, β-secretase enzyme (bace1), with one-step synthesized reduced graphene oxide |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987718/ https://www.ncbi.nlm.nih.gov/pubmed/35402415 http://dx.doi.org/10.3389/fbioe.2022.873811 |
work_keys_str_mv | AT deyjhilik electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide AT robertsakanksha electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide AT maharisubhasis electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide AT gandhisonu electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide AT tripathipremprakash electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide |